Axsome Therapeutics AXSM Payment Of Contingent Consideration
Payment Of Contingent Consideration at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept axsm:PaymentOfContingentConsideration.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's payment of contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's payment of contingent consideration?
- Axsome Therapeutics (AXSM) reported payment of contingent consideration of -$3.26M in Q1 2026.
- How has Axsome Therapeutics's payment of contingent consideration changed year-over-year?
- Axsome Therapeutics's payment of contingent consideration decreased by 42.8% year-over-year, from -$2.29M to -$3.26M.
- What is the long-term trend for Axsome Therapeutics's payment of contingent consideration?
- Over 2 years (2023 to 2025), Axsome Therapeutics's payment of contingent consideration has grown at a 26.5% compound annual growth rate (CAGR), from -$6.21M to -$9.94M.
- What does payment of contingent consideration mean?
- Cash paid to satisfy obligations related to performance milestones from past acquisitions.
- How do you interpret payment of contingent consideration?
- Payments indicate the successful achievement of development or commercial milestones, though they represent a cash outflow.
- How does payment of contingent consideration compare across companies?
- Specific to companies that grow through M&A; common in biotech for licensing or asset acquisition deals.